Dr. Steve Sitar, M.D
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 46
Licensed in California since 1991, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A49204 (first issued 1991; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 46
- Services billed
- 129
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Anaheim, CA | 160 |
| Amlodipine Besylate Other prescribers in Anaheim, CA | 157 |
| Atorvastatin Calcium Other prescribers in Anaheim, CA | 153 |
| Losartan Potassium Other prescribers in Anaheim, CA | 118 |
| Levothyroxine Sodium Other prescribers in Anaheim, CA | 103 |
| Pantoprazole Sodium Other prescribers in Anaheim, CA | 79 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Anaheim, CA | 66 |
| Famotidine Other prescribers in Anaheim, CA | 61 |
| Zolpidem Tartrate Other prescribers in Anaheim, CA | 55 |
| Eliquis (apixaban) Other prescribers in Anaheim, CA | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $2,335 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,741 |
|---|---|
| Insulet Corporation | $165 |
| Amgen Inc. | $146 |
| GlaxoSmithKline, LLC. | $122 |
| AstraZeneca Pharmaceuticals LP | $120 |
| Dexcom, Inc. | $40.97 |
| Travel and Lodging | $1,174 |
|---|---|
| Food and Beverage | $1,161 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 6, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $718 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 25, 2025 | Travel and Lodging travel to DFW Airport, TX · in-kind | $456 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $171,430 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Sanofi US Services Inc. · Completed · NCT06015308 - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Eli Lilly and Company · Completed · NCT04392154 - Continuous glucose monitoring system use in patients with diabetes a real world global registry
Dexcom, Inc. - A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.